Last reviewed · How we verify
nab-paclitaxel，Cisplatin
nab-paclitaxel and cisplatin work together as a chemotherapy combination to disrupt microtubule dynamics and cause DNA cross-linking, respectively, leading to cancer cell death.
nab-paclitaxel and cisplatin work together as a chemotherapy combination to disrupt microtubule dynamics and cause DNA cross-linking, respectively, leading to cancer cell death. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | nab-paclitaxel，Cisplatin |
|---|---|
| Sponsor | Yang Jianjun, PhD |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Target | Microtubules (paclitaxel); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
nab-paclitaxel (albumin-bound paclitaxel) stabilizes microtubules and prevents their disassembly, halting cell division. Cisplatin is a platinum-based agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
- Gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Alopecia
Key clinical trials
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC (PHASE2)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nab-paclitaxel，Cisplatin CI brief — competitive landscape report
- nab-paclitaxel，Cisplatin updates RSS · CI watch RSS
- Yang Jianjun, PhD portfolio CI